Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Societal CDMO, Inc. SCTL
$0.69
+$0.01 (1.46%)
На 18:05, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
59431613.00000000
-
week52high
1.86
-
week52low
0.62
-
Revenue
90214000
-
P/E TTM
-1
-
Beta
0.71764700
-
EPS
-0.32000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 20:00
Описание компании
Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022. Societal CDMO, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Lake Ryan David | D | 783050 | 1198 | 31 янв 2023 г. |
| ENLOE J DAVID JR | D | 973940 | 31046 | 20 янв 2023 г. |
| Lake Ryan David | D | 784248 | 14438 | 20 янв 2023 г. |
| ENLOE J DAVID JR | D | 287374 | 287374 | 19 янв 2023 г. |
| ENLOE J DAVID JR | A | 1004986 | 412401 | 19 янв 2023 г. |
| ENLOE J DAVID JR | D | 592585 | 56985 | 19 янв 2023 г. |
| ENLOE J DAVID JR | A | 649570 | 151515 | 19 янв 2023 г. |
| Lake Ryan David | D | 160929 | 160929 | 19 янв 2023 г. |
| Lake Ryan David | A | 798686 | 230944 | 19 янв 2023 г. |
| Lake Ryan David | D | 567742 | 28374 | 19 янв 2023 г. |
Новостная лента
Societal CDMO, Inc. (SCTL) CEO Q3 2022 Earnings Call Transcript
Seeking Alpha
09 ноя 2022 г. в 20:22
Societal CDMO, Inc. (NASDAQ:SCTL ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Stephanie Diaz - Investor Relations David Enloe - President and Chief Executive Officer Ryan Lake - Chief Financial Officer Conference Call Participants Matthew Hewitt - Craig-Hallum Max Smock - William Blair Mac Etoch - Stephens Inc. Operator Good day ladies and gentlemen, and welcome to the Societal CDMO Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Societal CDMO to Report Financial Results for Third Quarter 2022 on November 9, 2022
GlobeNewsWire
02 ноя 2022 г. в 16:05
Webcast Scheduled for Wednesday, November 9, 2022, at 4:30 p.m. Eastern Webcast Scheduled for Wednesday, November 9, 2022, at 4:30 p.m. Eastern
Societal CDMO, Inc.'s (SCTL) CEO David Enloe on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
10 авг 2022 г. в 20:36
Societal CDMO, Inc. (NASDAQ:SCTL ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Stephanie Diaz – Investor Relations David Enloe – President and Chief Executive Officer Ryan Lake – Chief Financial Officer Conference Call Participants Matthew Hewitt – Craig-Hallum Christine Rain – William Blair Operator Hello, thank you for standing by. And welcome to the Societal CDMO Second Quarter 2022 Conference Call.
Societal CDMO to Report Financial Results for Second Quarter 2022 on August 10, 2022
GlobeNewsWire
03 авг 2022 г. в 16:05
Webcast Scheduled for Wednesday, August 10, 2022, at 4:30 p.m. Eastern Webcast Scheduled for Wednesday, August 10, 2022, at 4:30 p.m. Eastern
Societal to Participate in Upcoming Investor Conferences
GlobeNewsWire
19 мая 2022 г. в 07:00
SAN DIEGO and GAINESVILLE, Ga., May 19, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will participate in three upcoming investor conferences.